A growing body of evidence has shown that STAT3 or GSK3β activation promotes tumor development and progression, as well as gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC) [58, 59]. This evidence concerns the gene GSK3B and pancreatic ductal adenocarcinoma.